Relay, Elevar Licensing Agreement for Lirafugratinib in Cholangiocarcinoma

 Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

https://www.globenewswire.com/news-release/2024/12/03/2990578/0/en/Relay-Therapeutics-and-Elevar-Therapeutics-Announce-Exclusive-Global-Licensing-Agreement-for-Lirafugratinib-in-FGFR2-Driven-Cholangiocarcinoma-and-Other-Solid-Tumors.html